Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P, on behalf of the Levemir Treat-to-Target Study Group: A 26-week randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people wih type 2 diabetes. Diabetes Care 29:1269–1274, 2006
In the abstract of the above-listed article, the sentence “In both groups, 70% of participants achieved an A1C ≤7.0%, but the proportion achieving this without hypoglycemia was higher with insulin detemir than with NPH insulin (26 vs. 16%, P = 0.008)” should read “In both groups, 70% of participants achieved an A1C ≤7.0%; there was a trend towards the proportion achieving this without hypoglycemia being higher with insulin detemir than with NPH insulin (34% vs. 25%, P = 0.052).”
On page 1271, in the middle column, the sentence “The proportion of participants reaching A1C ≤7.0% without hypoglycemia during the last 12 weeks of treatment was higher with insulin detemir (26%, 59 of 230) than NPH insulin (16%, 36 of 233; P = 0.008)” should read “The proportion of participants reaching A1C ≤7.0% without hypoglycemia during the last 12 weeks of treatment showed a trend towards being higher with insulin detemir (34%, 77 of 230) than NPH insulin (25%, 58 of 233; P = 0.052).”
